Figure 2.
Agilent ZORBAX Eclipse Plus C18, 2.1 x 150 mm, 3.5 µm 1 nmol/µL sample
Peak areas of early-, middle-, and late-eluting amino acids
|
|
Amino acid
|
Injection 1
|
Injection 2
|
Injection 3
|
Injection 4
|
Injection 5
|
Injection 6
|
Injection 7
|
Injection 8
|
Injection 9
|
Standard deviation
|
Mean
|
% RSD
|
|
Glutamic acid
|
90.7
|
93.7
|
92.4
|
93.1
|
93.8
|
94.7
|
92.5
|
95.7
|
93.2
|
1.43
|
93.3
|
1.5
|
|
Alanine
|
109.9
|
113.2
|
111.8
|
112.1
|
113.3
|
114.0
|
111.6
|
116.0
|
113.3
|
1.72
|
112.8
|
1.5
|
|
Cystine
|
153.2
|
157.0
|
155.0
|
157.0
|
157.8
|
159.0
|
154.4
|
162.6
|
158.0
|
2.79
|
157.1
|
1.8
|
|
Lysine
|
142.3
|
142.5
|
137.1
|
144.4
|
141.9
|
143.5
|
137.9
|
140.7
|
138.9
|
2.55
|
141.0
|
1.8
|
|
Proline
|
60.8
|
62.9
|
61.8
|
65.8
|
60.9
|
63.2
|
61.2
|
70.2
|
61.0
|
3.11
|
63.1
|
4.9
|
Outstanding method reproducibility is shown by an overlay of nine back-to-back injections and percent relative standard deviations (% RSDs) of peak areas.
|
|
|
|